Chairman Rick Scott and Ranking Member Kirsten Gillibrand highlighted their bipartisan CLEAR LABELS Act in an interview, emphasizing the need for country-of-origin labeling for prescription medicines to inform Americans about the origins of their medications.
Rick Scott committed to introducing and backing the CLEAR LABELS Act, which would require prescription medicines to be labeled with their country of origin.
The hearing emphasized the need for transparency and the importance of the CLEAR LABELS Act in addressing these concerns.
Rick Scott highlighted his commitment to increasing transparency in the U.S. medicine supply by stressing the importance of the CLEAR LABELS Act, which would require country-of-origin labeling for prescription medicines.
This is why I am taking action to address these threats immediately, with the introduction of my CLEAR LABELS Act. This bill would require country-of-origin labeling for pharmaceuticals... We can get country-of-origin labeling done now
Scott committed to advancing the CLEAR LABELS Act, which would require country-of-origin labeling for prescription drugs and related manufacturer/distributor information.
That’s why I’m leading the bipartisan CLEAR LABELS Act with Ranking Member Gillibrand to add country of origin labels to your medicines and help ensure every American can feel comfortable knowing what’s in their medicine cabinet.
Scott committed to leading the bipartisan CLEAR LABELS Act to add country-of-origin labels to prescription medicines.
“That’s why I’m leading the bipartisan CLEAR LABELS Act with Ranking Member Gillibrand to add country of origin labels to your medicines and help ensure every American can feel comfortable knowing what’s in their medicine cabinet.”
Scott committed to leading the bipartisan CLEAR LABELS Act to add country-of-origin labeling to prescription medicines.
Chairman Rick Scott’s bipartisan Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act received bicameral support with Congressman Rich McCormick leading the effort in the House of Representatives.
The CLEAR LABELS Act, introduced by Senator Rick Scott, gained support in the House with Congressman Rich McCormick leading the effort, indicating progress in advancing the legislation.
Chairman Rick Scott led a hearing entitled “Foreign Dependence: How China Captured America’s Drug Supply” to examine how Communist China has pursued global dominance in pharmaceutical manufacturing and how America’s trade, regulatory, and procurement decisions have contributed to the decline of America’s domestic production capacity.
Senator Rick Scott chaired a hearing focusing on China's influence over America's drug supply, underscoring the need for the CLEAR LABELS Act to enhance transparency.
Chairman Rick Scott led a hearing entitled “Truth in Labeling: Americans Deserve to Know Where Their Drugs Come From,” in which he exposed the serious risks of America’s overreliance on foreign-manufactured, generic drugs and announced his CLEAR LABELS Act, legislation requiring country-of-origin labeling for prescription drugs in the United States.
Senator Rick Scott announced the CLEAR LABELS Act during a hearing addressing the risks of reliance on foreign-manufactured generic drugs, advocating for country-of-origin labeling.
U.S. Senators Kirsten Gillibrand (D-NY) and Rick Scott introduced legislation—the Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act—to add country of origin labeling requirements to the U.S.’s prescription drug supply chain.
Senators Gillibrand and Scott introduced the CLEAR LABELS Act to mandate country-of-origin labeling for prescription drugs, aiming to enhance transparency in the pharmaceutical supply chain.
U.S. Senator Tommy Tuberville (R-AL) joined U.S. Sen. Rick Scott (R-FL) in introducing the Consumers Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act to add country of origin labeling requirements to the United States’ prescription drug supply chain.
Senator Tommy Tuberville co-sponsored the CLEAR LABELS Act with Senator Rick Scott, supporting the initiative to require country-of-origin labeling for prescription drugs.
Congress.gov identifies S.3788 as sponsored by Sen. Rick Scott, introduced on February 5, 2026, and still at the introduced/referred-to-committee stage rather than enacted.
Official bill status proves Scott introduced the Senate CLEAR LABELS Act, but the bill had not passed Congress or become law as of the cited record.
The Senate Aging Committee says Chairman Rick Scott and Ranking Member Kirsten Gillibrand introduced the CLEAR LABELS Act to add country-of-origin labeling requirements to the prescription drug supply chain.
This official committee release directly supports the promise’s introduction-and-support component and describes the bill’s intended country-of-origin labeling requirement.
GovInfo lists H.R. 8269 as the House CLEAR LABELS Act, introduced April 14, 2026, referred to committees, with the title requiring drug labeling to include manufacturer and supply-chain information.
The official House companion record shows bicameral advancement of the same policy, but only as an introduced/referred bill, not an enacted requirement.
The GovInfo bill text amends FDCA section 502(b) so finished drug labeling would identify original manufacturers of APIs, finished drug products, and packers or distributors.
Official bill text confirms the substance of the CLEAR LABELS proposal: prescription drug labeling transparency for original manufacturers and supply-chain information.
The Senate Aging Committee reported that Scott led a hearing on drug-origin transparency and announced the CLEAR LABELS Act as legislation requiring country-of-origin labeling for prescription drugs.
This shows concrete pre-introduction support: Scott used his committee chair role to hold a hearing and publicly announce the legislation.
The committee reported that Scott led another hearing and highlighted the bipartisan, bicameral CLEAR LABELS Act as a transparency measure for where medicines are manufactured.
This demonstrates continued support and public advancement after introduction, but still not final enactment of the labeling requirement.
The promise was to introduce and support the CLEAR LABELS Act, not necessarily to secure enactment of the labeling requirement. The evidence shows Rick Scott sponsored/introduced S.3788 on February 5, 2026, publicly announced it, chaired hearings promoting the policy, and helped build bipartisan and bicameral support during his current Senate term. Because the promised legislative introduction and support occurred, this counts as delivered even though the bill had not yet become law.
provider codex_cli · model gpt-5.5 · confidence 94%
partialsame_termA for effort
Senator Rick Scott introduced and advanced the CLEAR LABELS Act, including chairing relevant hearings and gaining bicameral support. However, there is no evidence that the Act was enacted into law or fully implemented as a requirement. His commitment and legislative effort are demonstrated, but the promise was only partially fulfilled as delivery on the final policy outcome is not documented.